Rocket Pharmaceuticals shares are trading higher after the company announced an FDA accelerated approval for KRESLADI for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, life-threatening pediatric genetic immunodeficiency.